# CXCL3 promotes liver cancer progression by modulating the tumor microenvironment via the PI3K/AKT/mTOR pathway

**Authors:** Yue Li, Tao Liu, Ziteng Cai, Chaonan Peng, Zhilei He, Lichun Liang, Bo Han, Ran Bi, Lei Liu, Weiqun Wang

PMC · DOI: 10.1371/journal.pone.0334639 · 2025-11-19

## TL;DR

CXCL3 promotes liver cancer by altering the tumor environment and activating the PI3K/AKT/mTOR pathway, leading to faster tumor growth and worse patient outcomes.

## Contribution

This study reveals a novel role of CXCL3 in liver cancer progression through microenvironment modulation and pathway activation.

## Key findings

- CXCL3 is upregulated in liver cancer and linked to reduced patient survival.
- CXCL3 activates the PI3K/AKT/mTOR pathway and promotes tumor cell growth and migration.
- CXCL3 overexpression in mice significantly increases tumor growth.

## Abstract

CXCL3, a member of the CXC chemokine family, has been increasingly implicated in the progression of various cancers, including hepatocellular carcinoma, due to its role in immune and inflammatory responses within the tumor microenvironment. This study aimed to investigate the expression and function of CXCL3 in liver cancer and to elucidate its underlying mechanisms. A combination of bioinformatics analysis, ELISA, RT-qPCR, immunohistochemistry, in vitro cell assays, and in vivo nude mouse models was employed to assess CXCL3 expression and function. The results showed that CXCL3 was significantly upregulated in hepatocellular carcinoma tissues and associated with reduced overall survival in patients. It promoted the proliferation, colony formation, and migration of liver cancer cells (Bel-7402, HepG2, and SMMC-7721) via exogenous, autocrine, and paracrine mechanisms, and recruited tumor-associated macrophages, neutrophils, and fibroblasts into the tumor microenvironment. Mechanistically, CXCL3 activated the PI3K/AKT/mTOR pathway by upregulating PI3K, p-PI3K, AKT, p-AKT, mTOR, and p-mTOR, while the mTOR inhibitor Torin 1 reversed these effects. Gene set enrichment analysis showed enrichment in immune-related pathways, including Toll-like receptor and chemokine signaling. In vivo, CXCL3 overexpression significantly promoted tumor growth in nude mice. These findings suggest CXCL3 facilitates liver cancer progression through tumor microenvironment modulation and PI3K/AKT/mTOR pathway activation.

## Linked entities

- **Genes:** CXCL3 (C-X-C motif chemokine ligand 3) [NCBI Gene 2921], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], Akt (Akt kinase) [NCBI Gene 41957], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475]
- **Chemicals:** Torin 1 (PubChem CID 49836027)
- **Diseases:** hepatocellular carcinoma (MONDO:0007256), liver cancer (MONDO:0002691)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Cxcl3 (C-X-C motif chemokine ligand 3) [NCBI Gene 330122] {aka Dcip1, Gm1960}
- **Diseases:** hepatocellular carcinoma (MESH:D006528), inflammatory (MESH:D007249), cancers (MESH:D009369)
- **Chemicals:** Torin 1 (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HepG2 — Homo sapiens (Human), Hepatoblastoma, Cancer cell line (CVCL_0027), SMMC-7721 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0534), Bel-7402 — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_5492)

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12629499/full.md

---
Source: https://tomesphere.com/paper/PMC12629499